PMID- 28482145
OWN - NLM
STAT- MEDLINE
DCOM- 20191009
LR  - 20191010
IS  - 1932-7005 (Electronic)
IS  - 1932-6254 (Linking)
VI  - 12
IP  - 2
DP  - 2018 Feb
TI  - A controlled release system for simultaneous delivery of three human perivascular 
      stem cell-derived factors for tissue repair and regeneration.
PG  - e1164-e1172
LID - 10.1002/term.2451 [doi]
AB  - Transplanted stem/progenitor cells improve tissue healing and regeneration 
      anatomically and functionally, mostly due to their secreted trophic factors. 
      However, harsh conditions at the site of injury, including hypoxia, oxidative and 
      inflammatory stress, increased fibrosis and insufficient angiogenesis, and in 
      some cases immunological response or incompatibility, are detrimental to stem 
      cell survival. To overcome the complexity and deficiencies of stem cell therapy, 
      the coacervate delivery platform is deemed promising because it offers controlled 
      and sustained release using heparin to recapitulate the binding and stabilization 
      of extracellular proteins by heparan sulphates in native tissues. Here we show 
      that recombinant alternatives of three key factors [vascular endothelial growth 
      factor (VEGF), monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 
      (IL-6)], commonly produced by perivascular stem cells under various stress 
      conditions, can be successfully incorporated into a heparin-based coacervate. We 
      characterized the release profile of the triply incorporated factors from the 
      complex coacervate. The coacervate-released factors were able to exert their 
      desired biological activities in vitro: VEGF stimulated human umbilical vein 
      endothelial cell proliferation, MCP-1 elevated macrophage migration and IL-6 
      increased IgM production by IL-6-dependent cell line. Thus, a controlled release 
      system can be used for simultaneous delivery of three stem cell-derived factors 
      and could be useful for tissue repair and regenerative medicine.
CI  - Copyright (c) 2017 John Wiley & Sons, Ltd.
FAU - Mansurov, Nurlan
AU  - Mansurov N
AD  - Department of Biomedical Sciences, Nazarbayev University School of Medicine, 
      Nazarbayev University, Astana, Kazakhstan.
FAU - Chen, William C W
AU  - Chen WCW
AD  - Research Laboratory of Electronics and Department of Biological Engineering, 
      Massachusetts Institute of Technology, Cambridge, MA, USA.
FAU - Awada, Hassan
AU  - Awada H
AD  - Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA.
AD  - McGowan Institute for Regenerative Medicine, University of Pittsburgh, 
      Pittsburgh, PA, USA.
FAU - Huard, Johnny
AU  - Huard J
AD  - Department of Orthopedic Surgery and Center for Tissue Engineering and Aging 
      Research, University of Texas Health Science Center at Houston, McGovern Medical 
      School, Houston, TX, USA.
AD  - Center for Sports Regenerative Medicine, Steadman Philippon Research Institute, 
      Vail, CO, USA.
FAU - Wang, Yadong
AU  - Wang Y
AD  - Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA.
AD  - McGowan Institute for Regenerative Medicine, University of Pittsburgh, 
      Pittsburgh, PA, USA.
FAU - Saparov, Arman
AU  - Saparov A
AUID- ORCID: 0000-0002-4407-1236
AD  - Department of Biomedical Sciences, Nazarbayev University School of Medicine, 
      Nazarbayev University, Astana, Kazakhstan.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20170720
PL  - England
TA  - J Tissue Eng Regen Med
JT  - Journal of tissue engineering and regenerative medicine
JID - 101308490
RN  - 0 (Chemokine CCL2)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Interleukin-6)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Animals
MH  - Blood Vessels/*cytology
MH  - Cell Line
MH  - Chemokine CCL2/pharmacology
MH  - Delayed-Action Preparations/*pharmacology
MH  - *Drug Delivery Systems
MH  - Heparin/pharmacology
MH  - Human Umbilical Vein Endothelial Cells/cytology/drug effects/metabolism
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins/*pharmacology
MH  - Interleukin-6/pharmacology
MH  - Mice
MH  - RAW 264.7 Cells
MH  - Regeneration/*drug effects
MH  - Stem Cells/*metabolism
MH  - Vascular Endothelial Growth Factor A/pharmacology
MH  - Wound Healing/*drug effects
OTO - NOTNLM
OT  - biomaterials
OT  - stem cells
OT  - tissue repair and regenerative medicine
EDAT- 2017/05/10 06:00
MHDA- 2019/10/11 06:00
CRDT- 2017/05/09 06:00
PHST- 2016/08/22 00:00 [received]
PHST- 2017/01/17 00:00 [revised]
PHST- 2017/05/04 00:00 [accepted]
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2019/10/11 06:00 [medline]
PHST- 2017/05/09 06:00 [entrez]
AID - 10.1002/term.2451 [doi]
PST - ppublish
SO  - J Tissue Eng Regen Med. 2018 Feb;12(2):e1164-e1172. doi: 10.1002/term.2451. Epub 
      2017 Jul 20.